J. Blanz

发表

Pharmacokinetics and Metabolism of Mitoxantrone A Review

U. Schuler, G. Ehninger, B. Proksch, 1990, Clinical pharmacokinetics.

Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates.

R. Gebhardt, G. Ehninger, K. Zeller, 1993, Cancer research.

Benzimidazoles as Potent and Orally Active mGlu5 Receptor Antagonists with an Improved PK Profile.

M. Fendt, I. Vranesic, S. Desrayaud, 2011, ACS medicinal chemistry letters.

Synthesis and structural elucidation of biliary excreted thioether derivatives of mitoxantrone.

G. Ehninger, K. Zeller, J. Blanz, 1994, Xenobiotica; the fate of foreign compounds in biological systems.

New Aspects in the Pharmacokinetics and Metabolism of Mitoxantrone

U. Schuler, G. Ehninger, B. Proksch, 1992 .

Quantitation of busulfan in plasma by high-performance liquid chromatography using postcolumn photolysis.

G. Ehninger, B. Proksch, K. Zeller, 1990, Journal of chromatography.

Increasing metabolic stability via the deuterium kinetic isotope effect: An example from a proline-amide-urea aminothiazole series of phosphatidylinositol-3 kinase alpha inhibitors.

C. Schnell, F. Blasco, G. Caravatti, 2016, Bioorganic & medicinal chemistry letters.

Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?

U. Schuler, G. Ehninger, B. Proksch, 1994, Bone marrow transplantation.

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.

G. Rummel, R. Wolf, F. Zécri, 2017, ACS medicinal chemistry letters.

On the Importance of Metabolic Stability to Achieve High Oral Exposures for Cyclic Peptides

T. Vorherr, M. Schaefer, K. Schroer, 2020, American Journal of Medicinal Chemistry.

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

Doriano Fabbro, Pascal Furet, Giorgio Caravatti, 2013, Bioorganic & medicinal chemistry letters.

Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.

C. Schnell, P. Furet, F. Blasco, 2015, Bioorganic & medicinal chemistry letters.

Micropreparative isolation and NMR structure elucidation of metabolites of the drug candidate 1-isopropyl-4-(4-isopropylphenyl)-6-(prop-2-yn-1-yloxy) quinazolin-2(1H)-one from rat bile and urine.

S. Desrayaud, J. Blanz, M. Ritzau, 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The Carcinostatic Activity of ^-(A^-Heterocyclic Carboxaldehyde Thiosemicarbazones II. 3-Hydroxypyridine-2-carboxaldehyde Thiosemicarbazone1

Erwin, J. Blanz, F. French, 2006 .

Preclinical pharmacokinetics and metabolism of MAK683, a clinical stage selective oral embryonic ectoderm development (EED) inhibitor for cancer treatment

Jiangwei Zhang, Chunye Zhang, M. Walles, 2021, Xenobiotica; the fate of foreign compounds in biological systems.

Use of a water-soluble busulfan formulation--pharmacokinetic studies in a canine model.

R Storb, H. Deeg, R. Storb, 1995, Blood.

Design of A Metabolically Stable Tritium-Tracer of the PI3Kδ-Inhibitor CDZ173 (Leniolisib) as a Tool to Study Liver Metabolites

P. Bross, K. Litherland, S. Desrayaud, 2018, Helvetica Chimica Acta.

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

Pascal Furet, Frédéric Stauffer, G. Rummel, 2016, ACS medicinal chemistry letters.

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

M. P. Dillon, P. Atadja, E. Li, 2022, Journal of medicinal chemistry.

Isolation and structure elucidation of urinary metabolites of mitoxantrone.

D. Waidelich, B. Greger, G. Ehninger, 1991, Cancer Research.

Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance

R. Pieters, K. Sikora, W. Siegert, 1991, Journal of Cancer Research and Clinical Oncology.

Discovery and profiling of a selective and efficacious Syk inhibitor.

Eric Vangrevelinghe, E. Vangrevelinghe, Christian C. Lee, 2015, Journal of medicinal chemistry.

Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.

G. Martiny-Baron, G. Fendrich, T. Troxler, 2016, Journal of medicinal chemistry.

Evaluation of relative MS response factors of drug metabolites for semi-quantitative assessment of chemical liabilities in drug discovery.

J. Blanz, P. Ramstein, David Pearson, 2017, Journal of mass spectrometry : JMS.

Detection and separation of the anthrapyrazole CI-941 and its metabolites in serum and urine by high-performance liquid chromatography.

G. Ehninger, B. Proksch, K. Zeller, 1994, Journal of chromatography. B, Biomedical applications.

Detection and identification of human urinary metabolites of biantrazole (CI-941).

G. Ehninger, K. Zeller, J. Blanz, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Syk inhibitors with high potency in presence of blood.

Jianwei Che, E. Vangrevelinghe, Christian C. Lee, 2014, Bioorganic & medicinal chemistry letters.

Evidence for oxidative activation of mitoxantrone in human, pig, and rat.

D. Waidelich, B. Greger, G. Ehninger, 1991, Drug Metabolism And Disposition.

The isolation and identification of indigo and indirubin from urine of a patient with leukemia.

G. Ehninger, K. Zeller, J. Blanz, 1989, Research communications in chemical pathology and pharmacology.

Corrigendum to “Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation” [Bioorg. Med. Chem. Lett. 23 (2013) 3741–3748]

D. Fabbro, J. Hamon, P. Furet, 2013 .

Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.

E. Vangrevelinghe, Christian C. Lee, G. Thoma, 2015, Bioorganic & medicinal chemistry letters.